...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: BIO Investor Forum, Oct 22-23

Zenith and Resverlogix are still on the schedule to present on Wednesday 10/23/19 at BIO Investor Forum in San Francisco as of the 10/15/19 posted schedule. Resverlogix presents at 9:45 AM and Zenith presents at 11:30 AM. 15 minutes time slots.

https://www.bio.org/events/bio-investor-forum

Share
New Message
Please login to post a reply